**Appendix Table C77. Outcome assessment: Treatment, glial tumors**

| **Study (Investigator, country, year)** | **Record Number** | **Group (N)** | **Primary Outcomes** | **Secondary Outcomes** | **F/U Frequency/Duration** |
| --- | --- | --- | --- | --- | --- |
| Berger, France, 1998 | 75380 | HSCT CPC (2) | Survival, tumor response | toxicity | 21 and 25 mo |
| Bouffet, France, 1997 | 78760 | 5 | Survival |  |  |
| Bouffet, France, 2000 | 78770 | 24 | Survival, EFS | Toxicity | 26 months |
| Busca, Italy, 1997 | 73190 | Ependymoma 2, Anaplastic Astrocytoma 1, Glioblastoma Multiforme 2, Oligodendroglioma 1 | OS, PFS, Tumor response | toxicity |  |
| Dunkel, United States, 1998 | 78780 | 10 | Survival |  |  |
| Finlay, United States | 1300 | 27 | EFS, OS | toxicity | 14 months |
| Grill, France, 1996 | 73240 | Ependymoma 16 | Tumor response, outcome, toxicity |  | 1.7 - 66 months |
| Grovas, United States, 1999 | 16600 | 11 | Tumor response, toxicity, survival |  | Study entry, +21, +42, +100 days and then every 2 months until 1 year after ASCR |
| Gururangan, United States, 1998 | 18000 | N=6, 1 ependymoma, 4 glioblastoma multiforme, 1 anaplastic astrocytoma | Progression, survival | toxicity, but not given by tumor type | NR |
| Jakacki, United States, 1999 | 15920 | 12 | OS, PFS, Tumor response | toxicity | 5-19months |
| Mahoney, United States, 1996 | 73250 | 7 | Toxicity, Tumor Response, PFS, OS |  | 2.6 years |
| Mason, United States, 1998 | 73180 | Ependymoma 15 | Survival, Progression, | Toxicity |  |
| Massimino, Italy, 2005 | 55220 | 21 | OS, PFS | TAE | Median FU 57mo (13-84) |
| Ozkaynak, United States, 2004 | 7850 | 6 | Disease Outcome | Toxicity |  |
| Shih, United States, 2008 | 2530 | 5 | Time to Progression, OS, Final Status |  | 73-3727 days |
| Thorarinsdottir, United States, 2007 | 73050 | 6 | Tumor Response, PFS, OS, Toxicity |  | median 22 months (8-82 mo) |
| Yule, United Kingdom, 1997 | 18960 | 4 | Tumor Response, Outcome, OS | Toxicity | median 27 months (12-34) |
| Zacharoulis, United States, 2007 | 73020 | 29 | EFS, OS | toxicity | .6-12+ years FU range |
| Gilheeney, United States, 2010 | 2187 | Anaplastic Astrocytoma (1); Oligoastrocytoma (1); Glioblastoma multiforme (2) | Survival | Harms | .1-7.7 years |